IL-37 Inhibits Inflammasome Activation and Disease Severity in Murine Aspergillosis

Silvia Moretti(University of Perugia), Silvia Bozza(University of Perugia), Vasileios Oikonomou(University of Perugia), Giorgia Renga(University of Perugia), Andrea Casagrande(Istituto Superiore di Sanità), Rossana G. Iannitti(University of Perugia), Matteo Puccetti(University of Perugia), Cecília Garlanda(Humanitas University), Soohyun Kim(University of Colorado Denver), Suzhao Li(University of Colorado Denver), Frank L. van de Veerdonk(Radboud University Nijmegen), Charles A. Dinarello(Radboud University Nijmegen), Luigina Romani(University of Perugia)
PLoS Pathogens
November 6, 2014
Cited by 164Open Access
Full Text

Abstract

Since IL-37 transgenic mice possesses broad anti-inflammatory properties, we assessed whether recombinant IL-37 affects inflammation in a murine model of invasive pulmonary aspergillosis. Recombinant human IL-37 was injected intraperitoneally into mice prior to infection and the effects on lung inflammation and inflammasome activation were evaluated. IL-37 markedly reduced NLRP3-dependent neutrophil recruitment and steady state mRNA levels of IL-1β production and mitigated lung inflammation and damage in a relevant clinical model, namely aspergillosis in mice with cystic fibrosis. The anti-inflammatory activity of IL-37 requires the IL-1 family decoy receptor TIR-8/SIGIRR. Thus, by preventing activation of the NLRP3 inflammasome and reducing IL-1β secretion, IL-37 functions as a broad spectrum inhibitor of the innate response to infection-mediated inflammation, and could be considered to be therapeutic in reducing the pulmonary damage due to non-resolving Aspergillus infection and disease.


Related Papers